Shandong Xinhua Pharmaceutical Company Limited
Informe acción XSEC:000756
Capitalización de mercado: CN¥9.7b
Shandong Xinhua Pharmaceutical Dividendos y recompras
Dividendo controles de criterios 4/6 Shandong Xinhua Pharmaceutical es una empresa que paga dividendos con una rentabilidad actual de 0.87% que está bien cubierta por los beneficios.
Información clave
0.9%
Rentabilidad por dividendo
-0.6%
Rendimiento de la recompra
Rendimiento total para el accionista 0.3% Rendimiento futuro de los dividendos n/a Crecimiento de los dividendos 16.8% Próxima fecha de pago de dividendos n/a Fecha ex dividendo n/a Dividendo por acción CN¥0.050 Ratio de pago 42%
Últimas actualizaciones de dividendos y recompras
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024 Aug 22
Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024 Jul 24
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 Jun 26
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 Mar 28
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 Jul 22
Mostrar todas las actualizaciones
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application Sep 13
Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs Sep 02
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024 Aug 22
Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024 Jul 24
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024 Jun 29
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 Jun 26
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024 May 29
Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 Mar 28
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient Feb 28
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate Jan 19
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 30
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes Dec 26
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) Dec 15
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat Oct 11
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration Aug 12
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee Jul 27
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 Jul 22 Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation Jul 15
Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation Jul 11
Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs Jun 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration Jun 14
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 25
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 24
Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments Oct 28
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022 Oct 13
Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes Sep 20
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022 Aug 19
Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022 Jul 30
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager Jul 04
Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022 Jul 01
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022 Jun 01
Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021 Apr 01
Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd. Apr 16
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Feb 24
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 23
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 02
Shandong Xinhua Pharmaceutical Company Limited Announces the Retirement of Certain Directors and Supervisors Nov 20
Shandong Xinhua Pharmaceutical Company Limited to Report Nine Months, 2020 Results on Oct 22, 2020 Oct 13
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 24, 2020 Aug 01
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) completed the acquisition of 33% stake in Shandong Xinhua Wanbo Chemical Industrial Co., Ltd from Hualu Holding Co., Ltd. Jul 31
Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: El pago de dividendos de 000756 ha sido volátil en los últimos 10 años.
Dividendo creciente: El pago de dividendos de 000756 ha aumentado en los últimos 10 años.
Rentabilidad por dividendo vs. Mercado Rentabilidad por dividendo de Shandong Xinhua Pharmaceutical vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de 000756 con la del mercado? Segmento Rentabilidad por dividendo Empresa (000756) 0.9% Suelo de mercado 25% (CN) 0.5% Techo de mercado 25% (CN) 2.1% Media de la industria (Pharmaceuticals) 1.6% Analista de previsiones (000756) (hasta 3 años) n/a
Dividendo destacado: El dividendo de 000756(0.87%) es más alto que el 25% inferior de los pagadores de dividendos del mercado CN (0.51%).
Alto dividendo: El (0.87%) del dividendo de 000756 es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado CN (2.06%).
Pago de beneficios a los accionistas
Cobertura de los beneficios: Con su razonablemente bajo ratio de pago (41.9%), los pagos de dividendos de 000756 están bien cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Con su bajo ratio de pago en efectivo (20.2%), los pagos de dividendos de 000756 están bien cubiertos por los flujos de caja.
Descubre empresas que pagan buenos dividendos Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}